Breaking News Instant updates and real-time market news.

PFE

Pfizer

$44.09

-0.28 (-0.63%)

, LLY

Eli Lilly

$110.41

-1.66 (-1.48%)

18:42
10/23/18
10/23
18:42
10/23/18
18:42

Pfizer, Eli Lilly: Phase 3 study of tanezumab met all three co-primary endpoints

Pfizer (PFE) and Eli Lilly and Company (LLY) announced complete results from a Phase 3 study evaluating the efficacy and safety of subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, in patients with osteoarthritis pain treated for 16 weeks. The study met all three co-primary efficacy endpoints, demonstrating that among patients with moderate-to-severe OA pain of the knee or hip, both dosing regimens of tanezumab were associated with a statistically significant improvement in pain, physical function and patient's global assessment of their OA, compared to placebo. These data were presented during a late-breaking oral session at the 2018 American College of Rheumatology/Association of Rheumatology for Health Professionals Annual Meeting in Chicago. "The results demonstrated by tanezumab in this study are particularly meaningful, given that patients had moderate-to-severe pain and were unable to achieve adequate pain relief with other treatment options, including opioids and NSAIDs," said Ken Verburg, tanezumab development team leader, Pfizer Global Product Development. "Our goal is to be able to offer tanezumab as a potential non-opioid treatment option for these patients suffering from osteoarthritis pain."

PFE

Pfizer

$44.09

-0.28 (-0.63%)

LLY

Eli Lilly

$110.41

-1.66 (-1.48%)

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 12

    Nov

PFE Pfizer
$44.09

-0.28 (-0.63%)

10/23/18
WOLF
10/23/18
INITIATION
Target $46
WOLF
Peer Perform
Pfizer reinitiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated Pfizer with a Peer Perform and $46 price target.
10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/08/18
GSCO
10/08/18
NO CHANGE
Target $36
GSCO
Sell
Ionis' Tegsedi to face commercial headwinds, says Goldman Sachs
After the FDA approved Ionis (IONS) and affiliate Akcea Therapeutics' (AKCA) Tegsedi for adult polyneuropathy of hereditary transthyretin-mediated amyloidosis, but with a black box warning, Goldman Sachs analyst Salveen Richter said he believes the drug faces commercial headwinds. He cites the underlying safety profile and requirement for consistent monitoring as well as the recent launch of Alnylam's (ALNY) Onpattro and expected launch of Pfizer's (PFE) tafamidis in the first half of 2019. Richter keeps a Sell rating on Ionis shares with a price target of $36.
10/02/18
PIPR
10/02/18
NO CHANGE
Target $100
PIPR
Neutral
AbbVie scripts for Humira relatively weak in Q3, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says new survey data from dermatologists and gastroenterologists indicate AbbVie's (ABBV) Humira is losing share faster in psoriasis and inflammatory bowel disease than in rheumatoid arthritis. In that management has called out psoriasis as a key driver of growth, the survey feedback may help explain Humira's relatively weak script trends for Q3, Raymond tells investors in a research note. The analyst believes dermatologists are embracing newer biologics such as Johnson & Johnson's (JNJ) Tremfya while gastroenterologists favor Takeda's Entyvio and increasingly Pfizer's (PFE) Xeljanz. Raymond remains cautious on shares of AbbVie ahead of European biosimilar erosion he expects to start this month. He keeps a Neutral rating on the stock with a $100 price target.
LLY Eli Lilly
$110.41

-1.66 (-1.48%)

10/23/18
WOLF
10/23/18
INITIATION
Target $119
WOLF
Peer Perform
Eli Lilly reinitiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated Eli Lilly with a Peer Perform and $119 price target.
10/22/18
HCWC
10/22/18
NO CHANGE
Target $54
HCWC
Neutral
Roche data should concern Nektar bulls, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay believes Roche's (RHHBY) preliminary data of RO6875281, a fibroblast activation protein targeted interleukin-2 variant, should concern the bulls of Nektar Therapeutics (NKTR). The 11% and 20% overall response rate for single agent RO6875281 in squamous cell head and neck cancer and melanoma is compelling, Chattopadhyay tells investors in a research note. Nektar's NKTR-214 had no monotherapy activity, and the early promise in combination with Opdivo "has faded potentially due to its limited PK profile," the analyst adds. In addition, Chattopadhyay believes the monotherapy activity with pegilodecakin, a pegylated IL-10 being developed by Eli Lily (LLY), further complicates the competitive landscape for NKTR-214. He believes the second generation of "not alpha" IL-2, which is poised to enter the clinic during 2019, could further "upend" NKTR-214 and might compel Nektar's partner Bristol-Myers Squibb (BMY) to "re-evaluate the aggressive development strategy that was outlined earlier this year." The analyst keeps a Neutral rating on Nektar with a $54 price target.
10/15/18
FBCO
10/15/18
INITIATION
Target $36
FBCO
Neutral
Elanco initiated with a Neutral at Credit Suisse
Credit Suisse analyst Erin Wright started Elanco (ELAN) with a Neutral rating and $36 price target. As the fourth-largest animal health therapeutics company, Elanco is highly levered to robust industry fundamentals across livestock and companion animal markets, and earnings growth should accelerate on dedicated innovation efforts and dramatically improving cost structure as a more nimble unencumbered entity, unchained to Eli Lilly (LLY), its large pharmaceutical parent, she contends.

TODAY'S FREE FLY STORIES

MZOR

Mazor Robotics

$58.30

-0.005 (-0.01%)

, MDT

Medtronic

$90.40

-3.28 (-3.50%)

17:32
11/19/18
11/19
17:32
11/19/18
17:32
Hot Stocks
Mazor Robotics shareholders approve merger agreement with Medtronic »

Mazor Robotics (MZOR)…

MZOR

Mazor Robotics

$58.30

-0.005 (-0.01%)

MDT

Medtronic

$90.40

-3.28 (-3.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

TNET

TriNet

$44.26

-0.5 (-1.12%)

17:29
11/19/18
11/19
17:29
11/19/18
17:29
Hot Stocks
TriNet names Samantha Wellington chief legal officer »

TriNet announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHKP

Check Point

$111.34

-2.83 (-2.48%)

, PANW

Palo Alto Networks

$163.45

-6.135 (-3.62%)

17:25
11/19/18
11/19
17:25
11/19/18
17:25
Conference/Events
Wedbush enterprise analyst to hold a group dinner meeting »

Enterprise Software…

CHKP

Check Point

$111.34

-2.83 (-2.48%)

PANW

Palo Alto Networks

$163.45

-6.135 (-3.62%)

FTNT

Fortinet

$67.78

-5.66 (-7.71%)

QLYS

Qualys

$69.24

-5.355 (-7.18%)

ZS

Zscaler

$33.07

-4.57 (-12.14%)

CYBR

CyberArk

$67.54

-7.19 (-9.62%)

SYMC

Symantec

$22.26

-0.83 (-3.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 26

    Nov

  • 26

    Nov

  • 28

    Nov

  • 28

    Nov

  • 29

    Nov

  • 29

    Nov

  • 03

    Dec

  • 03

    Dec

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

  • 10

    Dec

  • 09

    Jan

  • 10

    Jan

LMT

Lockheed Martin

$294.53

-6.53 (-2.17%)

17:24
11/19/18
11/19
17:24
11/19/18
17:24
Hot Stocks
Lockheed Martin awarded $240M Missile Defense contract »

Lockheed Martin is being…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

ALTM

Altus Midstream Company

$8.35

-0.28 (-3.24%)

17:20
11/19/18
11/19
17:20
11/19/18
17:20
Syndicate
Altus Midstream Company files to sell 360.5M shares of Class A common for holder »

Also files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALTM

Altus Midstream Company

$8.35

-0.28 (-3.24%)

17:19
11/19/18
11/19
17:19
11/19/18
17:19
Syndicate
Altus Midstream Company files to sell 12.56M shares of Class A common stock »

Issuable upon exercise of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$67.18

-0.97 (-1.42%)

, EGN

Energen

$73.27

-0.14 (-0.19%)

17:19
11/19/18
11/19
17:19
11/19/18
17:19
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises, Energen »

Carl Icahn reports 9.9%…

IEP

Icahn Enterprises

$67.18

-0.97 (-1.42%)

EGN

Energen

$73.27

-0.14 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

D

Dominion

$74.40

0.82 (1.11%)

, SCG

Scana

$43.70

0.75 (1.75%)

17:18
11/19/18
11/19
17:18
11/19/18
17:18
Hot Stocks
NCUC approves Dominion-SCANA combination »

The proposed combination…

D

Dominion

$74.40

0.82 (1.11%)

SCG

Scana

$43.70

0.75 (1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$269.40

-3.14 (-1.15%)

17:17
11/19/18
11/19
17:17
11/19/18
17:17
Hot Stocks
Northrop Grumman awarded $489.92M Air Force contract »

Northrop Grumman has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

CLDR

Cloudera

$11.23

-0.915 (-7.53%)

, HDP

Hortonworks

$14.52

-1.23 (-7.81%)

17:17
11/19/18
11/19
17:17
11/19/18
17:17
Hot Stocks
Hortonworks, Cloudera terminate waiting period for proposed merger »

Cloudera (CLDR) and…

CLDR

Cloudera

$11.23

-0.915 (-7.53%)

HDP

Hortonworks

$14.52

-1.23 (-7.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

PLSE

Pulse Biosciences

$13.35

0.545 (4.26%)

17:16
11/19/18
11/19
17:16
11/19/18
17:16
Syndicate
Pulse Biosciences commences $45M rights offering »

Pulse Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XYL

Xylem

$69.46

-1.38 (-1.95%)

17:15
11/19/18
11/19
17:15
11/19/18
17:15
Hot Stocks
Xylem signs MOU with Ethiopia government on water security »

Xylem has signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

NOC

Northrop Grumman

$269.40

-3.14 (-1.15%)

, SAIC

SAIC

$68.30

-2.18 (-3.09%)

17:12
11/19/18
11/19
17:12
11/19/18
17:12
Hot Stocks
Northrop Grumman, SAIC and others awarded $577.47M in Navy contracts »

Northrop Grumman (NOC),…

NOC

Northrop Grumman

$269.40

-3.14 (-1.15%)

SAIC

SAIC

$68.30

-2.18 (-3.09%)

GD

General Dynamics

$179.25

-3.86 (-2.11%)

BAH

Booz Allen

$51.90

-0.79 (-1.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 06

    Dec

  • 11

    Jan

IR

Ingersoll-Rand

$103.29

-1.045 (-1.00%)

17:12
11/19/18
11/19
17:12
11/19/18
17:12
Initiation
Ingersoll-Rand initiated  »

Ingersoll-Rand initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

CARB

Carbonite

$25.89

-1.78 (-6.43%)

17:11
11/19/18
11/19
17:11
11/19/18
17:11
Hot Stocks
Carbonite announces $50M stock repurchase program »

Carbonite announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PES

Pioneer Energy

$2.75

-0.01 (-0.36%)

17:11
11/19/18
11/19
17:11
11/19/18
17:11
Initiation
Pioneer Energy initiated  »

Pioneer Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

RNGR

Ranger Energy

$7.62

-0.53 (-6.50%)

17:10
11/19/18
11/19
17:10
11/19/18
17:10
Initiation
Ranger Energy initiated  »

Ranger Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SERV

ServiceMaster

$41.84

-0.58 (-1.37%)

17:09
11/19/18
11/19
17:09
11/19/18
17:09
Initiation
ServiceMaster initiated  »

ServiceMaster initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

KLIC

Kulicke & Soffa

$19.90

-0.96 (-4.60%)

17:06
11/19/18
11/19
17:06
11/19/18
17:06
Earnings
Kulicke & Soffa sees Q1 revenue $150M-$160M, consensus $191.06M »

Looking forward, Dr.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 11

    Dec

KLIC

Kulicke & Soffa

$19.90

-0.96 (-4.60%)

17:04
11/19/18
11/19
17:04
11/19/18
17:04
Earnings
Kulicke & Soffa reports Q4 EPS 45c versus 62c in Q4 last year »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 11

    Dec

ENTG

Entegris

$26.20

-1.07 (-3.92%)

17:04
11/19/18
11/19
17:04
11/19/18
17:04
Hot Stocks
Entegris announces additional $250M share repurchase authorization »

Entegris announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

SCI

Service Corp.

$44.69

-0.185 (-0.41%)

17:03
11/19/18
11/19
17:03
11/19/18
17:03
Hot Stocks
Service Corp. exec Sangalis sells 23,617 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEX

Emerald Expositions Events

$10.92

-0.63 (-5.45%)

17:02
11/19/18
11/19
17:02
11/19/18
17:02
Initiation
Emerald Expositions Events initiated  »

Emerald Expositions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTAS

Cintas

$179.63

-3.47 (-1.90%)

16:58
11/19/18
11/19
16:58
11/19/18
16:58
Initiation
Cintas initiated  »

Cintas initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARMK

Aramark

$35.81

-1.045 (-2.84%)

16:52
11/19/18
11/19
16:52
11/19/18
16:52
Initiation
Aramark initiated  »

Aramark initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.